Covalon Technologies (Covalon Technologies) LT-Debt-to-Total-Asset : 0.03 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Covalon Technologies LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Covalon Technologies's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.03.

Covalon Technologies's long-term debt to total assets ratio declined from Dec. 2022 (0.05) to Dec. 2023 (0.03). It may suggest that Covalon Technologies is progressively becoming less dependent on debt to grow their business.

Covalon Technologies LT-Debt-to-Total-Asset Historical Data

The historical data trend for Covalon Technologies's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Covalon Technologies LT-Debt-to-Total-Asset Chart

Covalon Technologies Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.16

0.08

0.05

0.04

Covalon Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.05	0.04	0.04	0.04	0.03

Covalon Technologies LT-Debt-to-Total-Asset Calculation

Covalon Technologies's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (A: Sep. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2023 )	/	Total Assets (A: Sep. 2023 )
	=	0.679	/	18.403
	=	0.04

Covalon Technologies's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	0.549	/	16.612
	=	0.03

Covalon Technologies (OTCPK:CVALF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Covalon Technologies LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Covalon Technologies's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Covalon Technologies (Covalon Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Covalon Technologies Ltd (OTCPK:CVALF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

COV:Canada

Address

1660 Tech Avenue, Unit 5, Mississauga, ON, CAN, L4W 5S7

Website

https://www.covalon.com

Covalon Technologies Ltd is principally engaged in the business of developing, licensing, and selling medical technologies. The company develops advanced wound care line which is designed for the treatment of a wide range of wounds; and infection prevention products such as MediClear PreOp which is a breathable, transparent, self-adhesive silicone barrier film that conforms to the contours of the body. It also develops perioperative care products. The company generates its revenue through development contracts, licensing agreements, and distribution contracts, and sales.